Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
OKYO Pharma Limited Sponsored ADR ( (OKYO) ) just unveiled an announcement.
On March 19, 2026, OKYO Pharma announced that non-executive director John Brancaccio acquired 5,000 of the company’s ordinary shares on Nasdaq at $1.61 per share. Following this purchase, Brancaccio’s total holding increased to 31,201 shares, signaling additional insider alignment with shareholders.
The company highlighted recent clinical progress for its lead asset, urcosimod, which has shown anti-inflammatory and pain-reducing activity in preclinical models and positive pain-reduction data in neuropathic corneal pain patients. OKYO recently completed a successful Phase 2 trial in NCP and plans to launch a roughly 150-patient Phase 2b/3 multiple-dose study in the first half of this year, underscoring its intent to advance within the ophthalmic therapeutics market.
The most recent analyst rating on (OKYO) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
Spark’s Take on OKYO Stock
According to Spark, TipRanks’ AI Analyst, OKYO is a Neutral.
The score is primarily held down by weak financial fundamentals (pre-revenue, ongoing losses, negative free cash flow, and negative equity) and bearish technicals (below key moving averages with negative MACD). Improved 2025 cost control and a debt-free balance sheet provide only limited offset.
To see Spark’s full report on OKYO stock, click here.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain and inflammatory eye diseases. The company’s flagship candidate, urcosimod, targets ocular inflammation and pain, and OKYO’s ordinary shares are listed on the Nasdaq Capital Market, positioning it within the specialty ophthalmology and pain-management segment.
Average Trading Volume: 271,117
Technical Sentiment Signal: Strong Sell
Current Market Cap: $83.22M
For detailed information about OKYO stock, go to TipRanks’ Stock Analysis page.